PEGylation of Interferon-β-1a

  title={PEGylation of Interferon-β-1a},
  author={B. Kieseier and P. Calabresi},
  journal={CNS Drugs},
  • B. Kieseier, P. Calabresi
  • Published 2012
  • Medicine
  • CNS Drugs
  • Achieving optimal patient benefit from biological therapies can be hindered by drug instability, rapid clearance requiring frequent dosing or potential immune reactions. One strategy for addressing these challenges is drug modification through PEGylation, a well established process by which one or more molecules of polyethylene glycol (PEG) are covalently attached to a biological or small-molecule drug, effectively transforming it into a therapy with improved pharmacokinetic and pharmacodynamic… CONTINUE READING
    42 Citations

    Figures, Tables, and Topics from this paper

    Incidence, characterization, and clinical impact analysis of peginterferon beta1a immunogenicity in patients with multiple sclerosis in the ADVANCE trial
    • 25
    Peginterferon beta-1a for the treatment of relapsing multiple sclerosis: A case series.
    • Barry Hendin
    • Medicine
    • Multiple sclerosis and related disorders
    • 2018
    • 1
    Peginterferon Beta-1a: A Review of Its Use in Patients with Relapsing-Remitting Multiple Sclerosis
    • 14


    Pegylated IFNs for chronic hepatitis C: an update
    • 22
    Pegylation: a novel process for modifying pharmacokinetics.
    • 701
    PEGylated interferon beta-1a: meeting an unmet medical need in the treatment of relapsing multiple sclerosis.
    • D. Baker, R. Pepinsky, +15 authors G. Davar
    • Medicine
    • Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research
    • 2010
    • 32
    PEG conjugates in clinical development or use as anticancer agents: an overview.
    • 361